ResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase 1 trial Proteomics secures exclusive biomakers license Smartphone-based respiratory diagnostic maker, ResApp Health (ASX:RAP), plunged by almost 30% after announcing its cough app might need a bit of fine tuning. An independent study released today revealed that ResApp’s COVID-19 […] The post ASX Health Stocks: ResApp’s COVID-conscious smartphone tool fails new test, shares crash 30pc appeared first on Gadgets Village .
Best Viral Videos Online